Search Results - "Chua, Daniel T. T."

Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis by Blanchard, Pierre, MD, Lee, Anne, Prof, Marguet, Sophie, MSc, Leclercq, Julie, MSc, Ng, Wai Tong, MD, Ma, Jun, Prof, Chan, Anthony T C, Prof, Huang, Pei-Yu, MD, Benhamou, Ellen, MD, Zhu, Guopei, MD, Chua, Daniel T T, MD, Chen, Yong, MD, Mai, Hai-Qiang, MD, Kwong, Dora L W, MD, Cheah, Shie Lee, MD, Moon, James, MSc, Tung, Yuk, MD, Chi, Kwan-Hwa, MD, Fountzilas, George, Prof, Zhang, Li, Prof, Hui, Edwin Pun, MD, Lu, Tai-Xiang, Prof, Bourhis, Jean, Prof, Pignon, Jean Pierre, Dr

“…Summary Background A previous individual patient data meta-analysis by the Meta-Analysis of Chemotherapy in Nasopharynx Carcinoma (MAC-NPC) collaborative group…”
Get full text

Factors contributing to the efficacy of concurrent–adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: Combined analyses of NPC-9901 and NPC-9902 Trials by Lee, Anne W.M, Tung, Stewart Y, Ngan, Roger K.C, Chappell, Rick, Chua, Daniel T.T, Lu, T.X, Siu, Lillian, Tan, Terence, Chan, L.K, Ng, W.T, Leung, T.W, Fu, Y.T, Au, Gordon K.H, Zhao, C, O’Sullivan, Brian, Tan, E.H, Lau, W.H

“…Abstract Background The current standard treatment for locoregionally advanced nasopharyngeal carcinoma (NPC) was conventional–fractionation radiotherapy plus…”
Get full text

Randomized Trial of Radiotherapy Plus Concurrent–Adjuvant Chemotherapy vs Radiotherapy Alone for Regionally Advanced Nasopharyngeal Carcinoma by Lee, Anne W. M., Tung, Stewart Y., Chua, Daniel T. T., Ngan, Roger K. C., Chappell, Rick, Tung, Raymond, Siu, Lillian, Ng, W. T., Sze, W. K., Au, Gordon K. H., Law, Stephen C. K., O'Sullivan, Brian, Yau, T. K., Leung, T. W., Au, Joseph S. K., Sze, W. M., Choi, C. W., Fung, K. K., Lau, Joseph T., Lau, W. H.

“…Background Current practice of adding concurrent–adjuvant chemotherapy to radiotherapy (CRT) for treating advanced nasopharyngeal carcinoma is based on the…”
Get full text

Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma by Chua, Daniel T. T., Wei, William I., Wong, Maria P., Sham, Jonathan S. T., Nicholls, John, Au, Gordon K. H.

“…Background This single‐center, phase II study assessed the safety/tolerability and initial efficacy of gefitinib in patients with nasopharyngeal carcinoma…”
Get full text

Intensity-modulated radiotherapy for early-stage nasopharyngeal carcinoma: A prospective study on disease control and preservation of salivary function by KWONG, Dora L. W, POW, Edmond H. N, SHAM, Jonathan S. T, MCMILLAN, Anne S, LEUNG, Lucullus H. T, LEUNG, W. Keung, CHUA, Daniel T. T, CHENG, Ashley C. K, WU, Po M, AU, Gordon K. H

“…Xerostomia is a uniform complication after radiotherapy (RT) for nasopharyngeal carcinoma (NPC). Dosimetric studies suggested that intensity-modulated RT…”
Get full text

Compassionate Use of Ripretinib for Patients With Metastatic Gastrointestinal Stromal Tumors: Taiwan and Hong Kong Experience by Lin, Li-Ching, Huang, Wen-Kuan, Yen, Chueh-Chuan, Yang, Ching-Yao, Sung, Meng-Ta, Wong, Natalie S. M., Chua, Daniel T. T., Lee, Sarah W. M., Chen, Jen-Shi, Yeh, Chun-Nan

“…Background Ripretinib was recently approved for the fourth-line targeted therapy for advanced gastrointestinal stromal tumor (GIST) refractory to imatinib,…”
Get full text

Corrigendum: Compassionate use of ripretinib for patients with metastatic gastrointestinal stromal tumors: Taiwan and Hong Kong experience by Lin, Li-Ching, Huang, Wen-Kuan, Yen, Chueh-Chuan, Yang, Ching-Yao, Sung, Meng-Ta, Wong, Natalie S.M., Chua, Daniel T. T., Lee, Sarah W. M., Chen, Jen-Shi, Yeh, Chun-Nan

Get full text

Management of the neck after chemoradiotherapy for head and neck cancers in Asia: consensus statement from the Asian Oncology Summit 2009 by Wee, Joseph T, Dr, Anderson, Benjamin O, Prof, Corry, June, FRANZCR, D'Cruz, Anil, Prof, Soo, Khee C, Prof, Qian, Chao-Nan, Prof, Chua, Daniel T, FRCR, Hicks, Rodney J, Prof, Goh, Christopher HK, FRCS, Khoo, James B, FRCR, Ong, Seng C, FRCR, Forastiere, Arlene A, Prof, Chan, Anthony T, Prof

“…Summary The addition of a planned neck dissection after radiotherapy has traditionally been considered standard of care for patients with positive neck-nodal…”
Get full text

Phase II trial of capecitabine plus cisplatin as first-line therapy in patients with metastatic nasopharyngeal cancer by Chua, Daniel T. T., Yiu, Harry Ho-Yin, Seetalarom, Kasan, Ng, Alice Wan-Ying, Kurnianda, Johan, Shotelersuk, Kanjana, Krishnan, Gopala, Hong, Ruey-Long, Yang, Muh-Hwa, Wang, Cheng-Hsu, Sze, Wing-Kin, Ng, Wai-Tong

“…Background Capecitabine is an oral fluoropyrimidine with single‐agent activity in metastatic nasopharyngeal carcinoma (NPC). This multicenter phase II study…”
Get full text

Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement by Tse, Vicki C, Ng, Wai Tong, Lee, Victor, Lee, Anne W M, Chua, Daniel T T, Chau, June, McGhee, Sarah M

“…XELOX (capecitabine + oxaliplatin) and FOLFOX 4 (5-FU + folinic acid + oxaliplatin) have shown similar improvements in survival in patients with metastatic…”
Get full text

Treatment outcome after radiotherapy alone for patients with Stage I–II nasopharyngeal carcinoma by Chua, Daniel T. T., Sham, Jonathan S. T., Kwong, Dora L. W., Au, Gordon K. H.

“…BACKGROUND The objective of this study was to review the long‐term treatment outcome of patients with American Joint Committee on Cancer (AJCC) 1997 Stage I–II…”
Get full text

Comparison of single versus fractionated dose of stereotactic radiotherapy for salvaging local failures of nasopharyngeal carcinoma: a matched-cohort analysis by Chua, Daniel T T, Wu, Shao-Xiong, Lee, Victor, Tsang, Janice

“…Local failure is an important cause of morbidity and mortality in nasopharyngeal carcinoma (NPC). Although surgery or brachytherapy may be feasible in selected…”
Get full text

What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis by Ribassin-Majed, Laureen, Marguet, Sophie, Lee, Anne W M, Ng, Wai Tong, Ma, Jun, Chan, Anthony T C, Huang, Pei-Yu, Zhu, Guopei, Chua, Daniel T T, Chen, Yong, Mai, Hai-Qiang, Kwong, Dora L W, Cheah, Shie-Lee, Moon, James, Tung, Yuk, Chi, Kwan-Hwa, Fountzilas, George, Bourhis, Jean, Pignon, Jean Pierre, Blanchard, Pierre

“…Purpose The role of adjuvant chemotherapy (AC) or induction chemotherapy (IC) in the treatment of locally advanced nasopharyngeal carcinoma is controversial…”
Get full text

Validation of a prognostic scoring system for locally recurrent nasopharyngeal carcinoma treated by stereotactic radiosurgery by Chua, Daniel T T, Hung, Kwan-Ngai, Lee, Victor, Ng, Sherry C Y, Tsang, Janice

“…Selection of patients with local failure of nasopharyngeal carcinoma (NPC) for appropriate type of salvage treatment can be difficult due to the lack of data…”
Get full text

Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non-squamous non-small cell lung cancer who have not received prior chemotherapy: A substudy of the Avastin in Lung trial by MOK, Tony SK, HSIA, Te-Chun, TSAI, Chun-Ming, TSANG, Kenneth, CHANG, Gee-Chen, CHANG, John Wen-Cheng, THITIYA, Sirisinha, SRIURANPONG, Virote, THONGPRASERT, Sumitra, CHUA, Daniel TT, MOORE, Nicola, MANEGOLD, Christian

“…Aim:  The phase III AVAiL study evaluated the efficacy and safety of the anti‐vascular epidermal growth factor agent bevacizumab combined with platinum‐based…”
Get full text

Prognostic impact of hemoglobin levels on treatment outcome in patients with nasopharyngeal carcinoma treated with sequential chemoradiotherapy or radiotherapy alone by Chua, Daniel T. T., Sham, Jonathan S. T., Choy, Damon T. K.

“…BACKGROUND The goal of the current study was to investigate the impact of hemoglobin (Hb) levels on treatment outcome in a randomized Phase III trial of…”
Get full text

Surrogate End Points for Overall Survival in Loco-Regionally Advanced Nasopharyngeal Carcinoma: An Individual Patient Data Meta-analysis by Rotolo, Federico, Pignon, Jean-Pierre, Bourhis, Jean, Marguet, Sophie, Leclercq, Julie, Tong Ng, Wai, Ma, Jun, Chan, Anthony T C, Huang, Pei-Yu, Zhu, Guopei, Chua, Daniel T T, Chen, Yong, Mai, Hai-Qiang, Kwong, Dora L W, Soong, Yoke Lim, Moon, James, Tung, Yuk, Chi, Kwan-Hwa, Fountzilas, George, Zhang, Li, Hui, Edwin Pun, Lee, Anne W M, Blanchard, Pierre, Michiels, Stefan

“…Our objective was to evaluate progression-free survival (PFS) and distant metastasis-free survival (DMFS) as surrogate end points for overall survival (OS) in…”
Get full text

Prognostic and therapeutic evaluation of nasopharyngeal carcinoma by dynamic contrast-enhanced (DCE), diffusion-weighted (DW) magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) by Mui, Alan W.L., Lee, Anne W.M., Lee, Victor H.F., Ng, W.T., Vardhanabhuti, Varut, Man, Shei S.Y., Chua, Daniel T.T., Law, Stephen C.K., Guan, X.Y.

“…Nasopharyngeal carcinoma (NPC) is an aggressive head and neck malignancy, and radiotherapy (with or without chemotherapy) is the primary treatment modality…”
Get full text

Complementary activation of peripheral natural killer cell immunity in nasopharyngeal carcinoma by Zheng, Ying, Cao, Kai‐Yuan, Ng, Sze Park, Chua, Daniel T.T., Sham, Jonathan S.T., Kwong, Dora L.W., Ng, Mun Hon, Lu, Liwei, Zheng, Bo‐Jian

“…NK cells and αβ‐ and γδ‐CTL play important roles in cellular immunity against tumors. We previously demonstrated that NPC patients have a quantitative and…”
Get full text

The predictive value of the 1997 American Joint Committee on Cancer stage classification in determining failure patterns in nasopharyngeal carcinoma by Chua, Daniel T. T., Sham, Jonathan S.T., Wei, William I., Ho, Wai‐Kuen, Au, Gordon K.H.

“…BACKGROUND A retrospective analysis of treatment outcomes in patients with nasopharyngeal carcinoma (NPC) was performed in which the newly revised 1997…”
Get full text